Diagnosis, Molecular Classification, and Treatment of T-Cell Lymphomas

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 25 June 2024 | Viewed by 304

Special Issue Editor


E-Mail Website
Guest Editor
Hematología Clínica, Hospital de la Santa Creu i Sant Pau (Barcelona), Universitat Autònoma de Barcelona/IIB Sant Pau, C/Sant Quintí, 89, 08041 Barcelona, Spain
Interests: lymphoma

Special Issue Information

Dear Colleagues,

T-cell lymphomas are a heterogeneous group of entities that still pose a diagnostic, classification and therapeutic challenge. Recent advances in molecular biology have made it possible to classify these entities better. However, this has not yet translated into significant therapy changes and even less in the adverse prognosis that characterizes most subtypes. Only CD30+, ALK+ and T-follicular helper lymphomas seem to have new therapies that could improve their prognosis.

The main objective of this edition is to comprehensively review the biology of the different entities that comprise T-lymphomas and how the diagnosis is reached for their classification. Likewise, the therapies in use with their degree of recommendation and the new molecules under study with potential applications will be discussed.

This Special Issue is crucial to understand advances in the various pathogenic pathways of T-cell lymphoma (epigenetic aberrations, TCR, SYK, JAK, PI3K, EZH1/2, HDAC, BCL2) to design and guide the management of very complex patients.

Dr. Silvana Novelli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • T-cell lymphomas
  • hematopoietic stem cell transplant
  • cellular therapy
  • monoclonal antibodies
  • bispecific T-cell engager
  • hypomethylating agents
  • TCR
  • SYK
  • JAK
  • PI3K
  • EZH1/2
  • HDAC
  • BCL2

Published Papers

This special issue is now open for submission.
Back to TopTop